Dr Arjun Balar speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about updated data from the KEYNOTE 57 trial. KEYNOTE 57 is a Phase II trial of pembrolizumab for patients with high-risk non-muscle invasive bladder cancer unresponsive to...
Original Article: Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer